Pneumonia Vaccines Market to Reach $10.21 Bn, Globally, by 2025 at 5% CAGR: AMR

PORTLAND, Oregon, June 6, 2019 /PRNewswire/ -- Allied Market Research recently published a report, titled, Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 2018–2025. The research offers a detailed analysis on changing market dynamics, key investment pockets, major segments, and market competition. According to the report, the global pneumonia vaccines market generated $7.08 billion in 2017, and is expected to reach $10.21 billion by 2025, growing at a CAGR of 5% from 2018 to 2025.

Growing incidence of pneumonia globally, increased government focus on immunization programs for pneumonia, and rise in focus for new pneumococcal vaccines propel the market growth. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the growth of the market. Conversely, the development of protein-based combination pneumococcal vaccines creates new opportunities for the growth of the market.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/2730 

Pneumococcal conjugate vaccine (PCV) segment to dominate through 2025

Among vaccine types, the pneumococcal conjugate vaccine (PCV) segment accounted for 89% of the overall market share in 2017 and would retain its dominance through 2025. This is because it is the most commonly used vaccine types among end users. However, the pneumococcal polysaccharide vaccine (PPV) segment would grow at the fastest CAGR of 5.4% during the forecast period. This is because these vaccines are less expensive than PCV and is popularly used in developing countries.

Prevnar 13 segment to be lucrative through 2025

Among product types, the Prevnar 13 segment was the largest in 2017, capturing 79.1% of the market share and would maintain its dominance through 2025. The segment would also grow at the fastest CAGR of 5.1% from 2018 to 2025. This is because it is one of the most efficient pneumonia vaccines adopted globally. The report also discusses Synflorix and Pneumovax23.

Private sector segment to lead the market through 2025

Among sectors, the private sector captured around 90% of the market share in 2017 and is likely to dominate the market through 2025. The same would achieve the fastest CAGR of 5.1% from 2018 to 2025. This is because major regions such as US and Europe commonly purchase pneumonia vaccine through private sector.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2730 

North America to maintain revenue lead, Asia Pacific to grow the fastest through 2025

The market in North America captured more than half of the market share in 2017 and is expected to dominate the market through 2025. This is due to wider pneumonia vaccination coverage in the region. However, the market in Asia Pacific would grow at a CAGR of 6.6% during the forecast period. This is due to growing efforts by UNICEF and WHO for improvement of pneumonia vaccine coverage and growing awareness of importance of pneumonia vaccines to prevent disease in the region. The other regions analyzed in the report include Europe and LAMEA (Latin America, Middle East, and Africa).

Key players of the industry

Leading market players analyzed in the research include Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience and Walvax Biotechnology Co., Ltd. These market players have adopted various strategies including collaborations, joint ventures, partnerships, expansions, and others to gain a strong position in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

BCG Vaccines Sales Market:  Opportunity Analysis and Industry Forecast, 2018 – 2025

Pneumonia Testing Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected] 
Web: https://www.alliedmarketresearch.com

SOURCE Allied Market Research